Tobramycin: Nursing Drug Guide, Nephrotoxicity & NCLEX Review

Nebcin is a historical U.S. brand for tobramycin sulfate injection; most inpatient units use generic Tobramycin Injection, USP (commonly 40 mg/mL, with some 10 mg/mL pediatric concentrations). Inhaled products (e.g., Tobi, Bethkis) and ophthalmic drops are different dosage forms with distinct indications—never substitute inhalation or topical products for IV/IM orders without prescriber and pharmacy verification.

Verify concentration (mg/mL), total mg/kg/day, and interval on every pass—aminoglycoside regimens are weight-based and frequently adjusted when renal function changes.

Tobramycin is a bactericidal aminoglycoside used for serious infections caused by susceptible gram-negative organisms. Nurses most often see it during inpatient treatment of sepsis, pneumonia, and meningitis when culture data support aminoglycoside therapy—tobramycin is frequently selected for Pseudomonas aeruginosa (including pulmonary exacerbations in cystic fibrosis) and other susceptible gram-negative organisms, often combined with beta-lactams or vancomycin for synergy or broader coverage.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor for persistent fever or clinical instability despite appropriate gram-negative coverage—may signal need for regimen change rather than automatic dose escalation.

Tobramycin binds the 30S ribosomal subunit and disrupts bacterial protein synthesis, producing concentration-dependent bactericidal activity; labeling lists activity against organisms including Pseudomonas aeruginosa, E. coli, and Klebsiella species among others. Because aminoglycosides penetrate poorly into some tissues and require active renal clearance, tissue levels and serum concentrations must be monitored—especially when renal perfusion drops or concurrent nephrotoxic drugs are on the MAR.

Renal proximal tubular uptake concentrates tobramycin in kidney cells, which explains dose- and duration-related nephrotoxicity. Cochlear and vestibular hair cells are similarly vulnerable, producing auditory and vestibular toxicity that labeling states is usually irreversible.

Individualize to infection severity, renal function, and pharmacy protocol. Labeling emphasizes weight-based dosing and renal adjustment—never copy a neighbor patient’s mg dose without recalculating mg/kg.

Hemodialysis: Removes approximately 25% to 70% of dose depending on dialysis duration and modality per labeling—coordinate post-dialysis dosing with pharmacy.

Missed dose: Not specified in the reviewed prescribing information; follow prescriber or pharmacy guidance and do not double doses without authorization.

• IV: Infuse diluted doses over 20–60 minutes; periods under 20 minutes are not recommended because peaks may exceed 12 mcg/mL
• Peak/trough targets: Labeling warns against prolonged peaks >12 mcg/mL and troughs >2 mcg/mL because toxicity risk rises
• Half-life: About 2 hours with normal renal function; prolongs as creatinine clearance falls—adjust interval per labeling tables
• Duration of therapy: Usually 7–10 days; longer courses increase cumulative nephro- and ototoxicity risk
• Dialysis: Significant removal with hemodialysis—pharmacy typically redoses after dialysis per protocol

Pretreatment checks

• Current weight and calculated mg/kg/day versus MAR order—independent double-check with pharmacy when possible
• Latest BMP: creatinine, BUN, electrolytes; trend eGFR across the admission
• Allergy history to tobramycin or other aminoglycosides (cross-sensitivity possible)
• Concurrent nephrotoxic or ototoxic drugs—especially loop diuretics such as furosemide, vancomycin, amphotericin, or other aminoglycosides
• Whether trough or peak draw is due before the next scheduled dose
• History of aminoglycoside ototoxicity, maternal MT-RNR1 variant, or planned prolonged course (>10 days increases risk per labeling)
• Sulfite sensitivity—product contains sodium metabisulfite

Contraindications

• Hypersensitivity to tobramycin
• Serious toxic reaction to another aminoglycoside (potential cross-sensitivity per labeling)

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

IV: Tobramycin injection must be diluted before administration. For adults, use 50–100 mL of 0.9% sodium chloride or 5% dextrose and infuse over 20–60 minutes per labeling (infusions under 20 minutes are not recommended). Do not physically premix with other drugs in the same container.

• Verify mg/kg, concentration (mg/mL), and total volume with an independent double-check
• Use IV medication administration best practice: dedicated line or proper flush sequence when sharing access
• Document infusion start and stop times—critical for peak/trough interpretation
• IM: May be given undiluted deep IM when IV access unavailable; rotate sites

• Defervescence and hemodynamic stabilization in sepsis when organism is susceptible—track fever trends with source-control measures
• Improving white blood cell trend and clinical source control (e.g., clearer lungs, controlled urine source)
• Culture and sensitivity data supporting continued aminoglycoside use
• Therapeutic drug levels within pharmacy target range without rising creatinine or auditory symptoms

Aminoglycoside toxicity can progress while the patient still appears hemodynamically stable—do not wait for dialysis-level renal failure before escalating.

• Creatinine or BUN rising sharply across serial BMP values—possible acute kidney injury
• Oliguria or urine output falling despite adequate perfusion
• New ringing in the ears, hearing loss, or vertigo—may indicate irreversible eighth cranial nerve injury
• Trough above 2 mcg/mL or peak prolonged above 12 mcg/mL per labeling thresholds
• Concurrent potent diuretic on the MAR with accelerating renal decline
• Hypersensitivity reaction, severe rash, or bronchospasm

↔On a small screen, swipe or scroll sideways to see the full table.

Whenever adverse reactions are moderate or severe, tobramycin dosage should be reduced or therapy withdrawn per labeling and prescriber direction.

Principal signs of overdose or excessive exposure reflect exaggerated aminoglycoside toxicity: renal dysfunction, auditory and vestibular injury, and neuromuscular weakness in severe cases. Labeling notes toxicity may occur with therapy longer than 10 days, adult doses above 5 mg/kg/day, pediatric doses above 7.5 mg/kg/day, or when renal impairment is present without appropriate dose adjustment.

Antidote

Not specified in the reviewed prescribing information — there is no listed specific reversing agent. Treatment is supportive.

Management per labeling

• Hold or adjust therapy with prescriber and pharmacy input
• Monitor renal function, fluid status, and neurologic/auditory symptoms closely
• Hemodialysis may aid removal—approximately 25% to 70% depending on dialysis modality and duration per labeling
• Contact local poison control or medical toxicology services per facility protocol for significant overdose or instability

• Gentamicin vs tobramycin vs amikacin — all aminoglycosides but not interchangeable; verify drug name, mg/kg/day, and interval on every pass
• IV injection vs inhaled tobramycin (Tobi/Bethkis) — wrong route can under-treat systemic infection or over-expose lungs; read order route and product label every time
• Nebcin / Tobramycin Injection USP — verbal orders may be misheard; confirm generic name, route, and total milligrams in writing
• 10 mg/mL vs 40 mg/mL vials — triple-check concentration before drawing dose; use leading zeros per institutional policy
• mg vs mg/kg — most errors occur when a total mg dose is copied without weight recalculation
• Duplicate aminoglycoside therapy — home or prior-facility orders may persist; perform medication reconciliation at every transition

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Serum creatinine, BUN, and eGFR—at least daily during therapy; more often if declining
• Peak and trough tobramycin levels per pharmacy protocol; avoid trough >2 mcg/mL and prolonged peak >12 mcg/mL
• Urine output and net fluid balance each shift
• Auditory symptoms (tinnitus, hearing loss) and vestibular symptoms (vertigo, imbalance)
• Signs of neuromuscular weakness when neuromuscular blockers are co-administered

Document

• Weight used for mg/kg calculation, total dose, dilution volume, infusion start/stop times
• Level draw times relative to scheduled doses
• Creatinine trend and any hold parameters triggered
• Patient teaching on reporting tinnitus, hearing changes, and decreased urination

• Report ringing in the ears, hearing loss, dizziness, or balance problems immediately—these may indicate permanent injury
• Notify the nurse if urination decreases or you feel more swollen or short of breath
• IV tobramycin requires the full infusion time—do not ask staff to speed the pump
• Tell your care team about all medicines including OTC pain relievers and herbal products
• Understand that blood draws for drug levels are part of safe therapy—not optional extras
• Ask when to follow up for hearing assessment if aminoglycoside therapy was prolonged

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Practice NCLEX-style clinical judgment practice for tobramycin with a tabbed Pseudomonas exacerbation case (MAR, labs, I&O, nursing notes), then priority action, SATA cue recognition, renal trend interpretation, matrix urgency matching, IV infusion timing, and supportive-toxicity cloze—each item targets peak/trough nephro- and ototoxicity with an explicit evaluate outcomes step after the prescriber adjusts therapy.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.